scispace - formally typeset
E

Efraim H. Rosenberg

Researcher at Netherlands Cancer Institute

Publications -  36
Citations -  2166

Efraim H. Rosenberg is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 18, co-authored 28 publications receiving 2011 citations. Previous affiliations of Efraim H. Rosenberg include VU University Medical Center & Leiden University Medical Center.

Papers
More filters
Journal ArticleDOI

RAD51B in Familial Breast Cancer

Liisa M. Pelttari, +115 more
- 05 May 2016 - 
TL;DR: It is suggested that loss-of-function mutations in RAD 51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.
Journal ArticleDOI

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

TL;DR: This is the first report providing clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated ovarian cancer, and the encouraging antitumor activity observed in patients who were refractory or resistant to first-line therapy warrants further development.
Journal ArticleDOI

Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHD gene

TL;DR: It is demonstrated that the maternally derived wild‐type SDHD allele is lost in tumors from mutation‐carrying patients, indicating that SDHD functions as a tumor suppressor gene.
Journal ArticleDOI

Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy

TL;DR: Two patients are reported whose CSF showed the marker of folinic acid–responsive seizures, but who responded clinically to pyridoxine, and genetic and biochemical testing was performed on these patients, and seven others, to determine the relation between these two disorders.